- Home
- EXAS vs WDI Comparison
EXAS vs WDI Comparison
Compare EXAS & WDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- WDI
- Stock Information
- Founded
- EXAS 1995
- WDI 2021
- Country
- EXAS United States
- WDI United States
- Employees
- EXAS N/A
- WDI N/A
- Industry
- EXAS Medical Specialities
- WDI Trusts Except Educational Religious and Charitable
- Sector
- EXAS Health Care
- WDI Finance
- Exchange
- EXAS Nasdaq
- WDI Nasdaq
- Market Cap
- EXAS 10.7B
- WDI 753.0M
- IPO Year
- EXAS N/A
- WDI N/A
- Fundamental
- Price
- EXAS $56.28
- WDI $14.70
- Analyst Decision
- EXAS Strong Buy
- WDI
- Analyst Count
- EXAS 20
- WDI 0
- Target Price
- EXAS $70.68
- WDI N/A
- AVG Volume (30 Days)
- EXAS 3.6M
- WDI 192.6K
- Earning Date
- EXAS 07-30-2025
- WDI 01-01-0001
- Dividend Yield
- EXAS N/A
- WDI 11.80%
- EPS Growth
- EXAS N/A
- WDI N/A
- EPS
- EXAS N/A
- WDI 1.12
- Revenue
- EXAS $2,828,128,000.00
- WDI N/A
- Revenue This Year
- EXAS $14.58
- WDI N/A
- Revenue Next Year
- EXAS $12.75
- WDI N/A
- P/E Ratio
- EXAS N/A
- WDI $12.82
- Revenue Growth
- EXAS 11.57
- WDI N/A
- 52 Week Low
- EXAS $39.97
- WDI $12.16
- 52 Week High
- EXAS $72.83
- WDI $14.69
- Technical
- Relative Strength Index (RSI)
- EXAS 61.48
- WDI 67.47
- Support Level
- EXAS $55.26
- WDI $14.50
- Resistance Level
- EXAS $58.68
- WDI $14.68
- Average True Range (ATR)
- EXAS 1.98
- WDI 0.16
- MACD
- EXAS -0.14
- WDI 0.02
- Stochastic Oscillator
- EXAS 64.86
- WDI 100.00
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.